BioSpace News Archive

Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, today announced that its lead product, TTI-101, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF).

Strata Oncology, Inc., a next-generation precision oncology company enabling smarter and earlier cancer treatment, today announced that two new health system partners.

CorePath is excited to announce a partnership with Cizzle Biotechnology, a UK based diagnostics developer, to develop and offer a proprietary early-stage lung cancer test throughout the United States.

Lassen Therapeutics, a biotech company developing breakthrough antibody therapeutics as potential treatments for fibrosis, rare diseases and oncology, today announced plans to present a poster on IL-11 receptor-blocking as a novel therapeutic approach for lung fibrosis at the upcoming Keystone Symposia Conference.

According to QY Research Medical, the implantable cardiac monitors market was valued at $500.02 million in 2020, and is projected to reach $974.42 million by 2030, growing at a CAGR of 7.5% from 2021 to 2030.

According to QY Research Medical, the atrial fibrillation market size was valued at $1,825.85 million in 2020, and is projected to reach $3,370.70 million by 2030, growing at a CAGR of 6.7% from 2021 to 2030.

The global ureteral stents market was accounted at $362.34 million in 2020, and is projected to hit around $625.17 million by 2030, growing at a CAGR of 5.9% from 2021 to 2030.

According to the report “Global Respiratory Syncytial Virus Market” – Industry Dynamics, Market Size, and Opportunity Forecast to 2027” published by Astute Analytica, Respiratory Syncytial market has been estimated to have a CAGR of 14.9% during the forecast period, globally.

Ken D’Entremont, Chief Executive Officer, Medexus Pharmaceuticals (Medexus) (TSX: MDP) shares his Company’s story in an interview with TMX Group.

Brand Institute is proud to announce working with Mitsubishi Tanabe in developing the brand name Radicava ORS®, approved by the Food and Drug Administration (FDA) on May 12, 2022.